0000899243-19-001869.txt : 20190124 0000899243-19-001869.hdr.sgml : 20190124 20190124160622 ACCESSION NUMBER: 0000899243-19-001869 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190122 FILED AS OF DATE: 20190124 DATE AS OF CHANGE: 20190124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oxtoby Andrew CENTRAL INDEX KEY: 0001765473 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 19540064 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-22 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001765473 Oxtoby Andrew C/O AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 Chief Commercial Officer Common Stock, $0.0001 par value 2019-01-22 4 A 0 12000 0.00 A 12000 D Stock Option (right to buy) 21.94 2019-01-22 4 A 0 150000 0.00 A 2029-01-22 Common Stock 150000 150000 D These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 22, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Douglas T. Sheehy, as Attorney-in-Fact for Andrew Oxtoby 2019-01-24